Stock for DBV Technologies S.A. (NASDAQ: DBVT) remained relatively stable throughout the day and began climbing in the current market. After little movement during the regular session, DBVT stock steadily rose by an impressive 14.74%. Traders continue to anticipate whether or not this steady growth spurt shall continue upon this trajectory, as the premarket session continues. The market anticipates further growth, given the significantly noticeable gap which is likely to be filled in.

Chatter amongst traders on social media spheres indicates a degree of caution with which the market views this reversal. The bearish trend the stock has maintained since the prior year is cause for this widespread skepticism regarding the stock. However, the DBVT stock is currently part of a growth spurt that biotech and pharmaceutical firms have been recently experiencing. The healthcare sector is seeing a wide reallocation of financing, with the threat of the Covid-19 pandemic being seriously downgraded.

DBVT Participation in AAAAI Conference

Last month, DBV Technologies announced participation in the AAAAI Conference 2022, which will be held at the end of March. The American Academy of Allergy Asthma and Immunology is a prestigious platform likely to boost credibility in DBVT. The scientific presentations delivered by the company would include a clinical and a non-clinical poster, which is certain to bring DBVT under the spotlight. The company’s participation in the conference will shed light on peanut allergy treatment with respect to epinephrine prescription. The DBVT team will further highlight the variable of healthcare cost, within this critical discussion.

Viaskin Development and DBVT

During the course of the conference, DBVT will share crucial information regarding clinical trials on Viaskin. This is a product the company is currently developing to address peanut allergies. Given that peanut allergies constitute the most common allergic condition amongst American children, this could potentially be a breakthrough. Investors certainly realize the value addition this could contribute towards, something evident by the management’s optimism surrounding this treatment. Similarly, the growth trajectory undertaken by the DBVT stock could potentially be an indicator of this gleeful anticipation.

Conclusion

Retail investors are closely watching the DBVT stock, with many anticipating the realization of even bigger growth. This is presumably a part of a broader growth spurt the biopharmaceutical sector is currently witnessing. DBV Technology’s participation in the upcoming AAAAI Conference could further raise market perception towards the stock.

Indonesia Energy Corporation Limited (NYSEAMERICAN: INDO) stock continued its growth trend-momentum of the last two months. Within this period, the stock peaked at a whopping 417.9% price rise. Zeroing in on today’s movement alone, there had been a persistent climb of 37.65%. The resultant growth trajectory was maintained well into the pre-market session.

Global Energy Crisis

The global energy sectors, particularly those that which is focused on oil and gas, are being watched closely by market participants. This is especially a result of the heightened demand, in wake of economic sanctions imposed against Russia. Indonesia Energy Corporation (IEC), along with other market giants, has been under the spotlight, given these fundamental shifts in the energy sectors. Demand for fossil fuels has also been reaching new heights amidst easing Covid-19 restrictions

With the pressure on limited supply lines, and demand reaching new heights given easing Covid-19 restrictions, all eyes are on oil drillers and suppliers such as IEC.

Expansion of Production Capacity and Implications for INDO Stock

An official announcement from the IEC earlier in January had turned the steering wheel on the company’s stock valuation. News of the imminent drilling of two oil wells have caused the company’s market capitalization to balloon from $20.8M to a staggering $107.4M. The company further stated its plans on beginning drilling on a third oil well before June of this year. The announcement further boosts the company’s profitability potential. With crude oil prices rising over $118 per barrel, which is the highest its been at since 2013, the sector is looking at strengthened cash flow positions. The INDO stock movement seen throughout this week reflects these anticipations of the wider market.

Sustainable Diversification for INDO Stock

Another potential reason as to why INDO has presumably gained the confidence of investors is a recent deal signed with Fusion Fuel Green later last month. The Irish company, being a highly promising player in the clean energy hydrogen sector offers sustainability to IEC’s future prospects. The agreement entails an installation of a state-of-the-art hydrogen production facility in Sinai. Investors are typically wary of companies that tie all their eggs in one basket. This is especially true when the basket is as volatile and unpredictable as the energy sector. This sustainable diversity, therefore, instills confidence in the company’s long-term prospects and growth potential.

Conclusion

The INDO stock is a big mover and has maintained its impressive growth trajectory for the last two weeks. Announcements of imminent oil drilling ambitions amidst the global energy crisis bring confidence amongst traders of the company’s growth potential. Its sustained diversification further emphasizes its long term prospects.

Stock for InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) has been seeing much chatter amongst market participants, particularly across social media platforms. After a bearish day in the regular hours of trade −0.040 (10.70%), the stock continues its decline into the afterhours . This comes after a week of consistently high gains of a whopping 53.46%, which saw a turn around earlier yesterday, putting out the bullish spell on the stock. Traders continue to speculate in regards to the direction this penny stock will take, and whether or not its upward movement is worth betting on. As the volatility continues, retail investors are eagerly watching to see whether or not the target price will be achieved.

Media Attention on NVIV over the Years

Apart from an announcement to partake in the Wainwright Bioconnect Conference earlier this year, there has been little mention of the company’s affairs which could potentially be linked to this growth spurt, and increased trade volume. The biotech company, which is engaged in research and clinical trials, is one that has frequently garnered media attention in the previous years. NVIV stock tanked nearly 60% back in 2017, after news of the death of a third candidate that had undergone spinal cord implant. Although investigators could not determine a conclusive link between Invivo’s Biotechnology and the demise of the patient, the program was discontinued.

Market Growth Potential

One noteworthy development from yesterday was a research report published yesterday by research and consultancy specialist, A2Z Market Research on the spinal cord treatment market. The study deemed the time frame from 2022 to 2029 as one where “robust expansion” would be experienced across the market. Invivo Therapeutics (NVIV) was profiled within this research, alongside major players such as Pfizer Inc, Norvatis AG, Pharmicell Co, and many others. Given these findings, it is clear that the market anticipates growth in the coming years, and Invivo, being a firm which specializes precisely on spinal cord treatment is poised to share in on these long-term gains.

Conclusion

The NVIV stock has left traders impressed with its high growth trajectory over the prior week. The sudden downturn in the afterhours and volatility is being watched with close anticipation. Invivo, as per a recent market research report, is part of a specific market niche in the biotech realm that expects substantial expansion in the coming years.

HOOKIPA Pharma Inc. (HOOK) has plunged -22.22% at $1.96 in the current market on the last check Wednesday. The stock of HOOK completed the previous trading session at $2.52. The price range of the company’s shares was between $2.36 and $2.7899.

Expected Public Offering

This volatility in trading had been brought about, following the announcement of Hookipa Pharma’s announcement of an imminent public offering of two distinct classes of stock, the first of is which is of the common category, with the second being non-voting preferential convertible stock. This offering is likely to deliver an immediate injection of funds into Hookipa Pharma which would enable potential growth, yet to be realized. Traders are thus hoping to cash in on the newfound confidence in the HOOK stock given this announcement, which is likely to see steady growth once the public offering takes place.

Collaboration with Gilead Sciences

This is not the first-time onlookers have been eyeing the HOOK stock with optimistic anticipation. Earlier last month, when Hookipa amended the terms of its collaborative agreement with the pharmaceutical giant, Gilead Sciences Inc (NASDAQ: GILD), stock prices soared. This amendment was made to an existing contract signed in April of 2018, where Hookipa was granted exclusive rights for the development of hepatitis B and HIV immunotherapies. As a result, the company saw its first month without net loss in value since May of 2021. Following the amendment in the contract, Hookipa was paid a $4 million funding package to advance phase 1 trials under the HIV program signed.

As the world continues to recover from the Covid-19 outbreak, with vaccination rates seeing a continuous increase, and global containment restrictions being eased, the pharmaceutical industry is returning its focus to serious diseases which require immediate attention. The likely trend expected is for the pharmaceutical industry to make investments around biotech sectors that received little attention in the prior years.

Conclusion

The volatility observed in HOOK stock price can be attributed to a significant anticipated gain, following plans of a public offering in the near future. Furthermore, amendments to an existing agreement with Gilead Sciences and a $4 million funding indicate a shift in the pharmaceutical industry, away from Covid-19 related investments.

Traders looking to bag high gains from penny stocks have closely been paying attention to the stock of ECMOHO Limited (MOHO), which saw a shoot up of 81.4% in a mere seven-hour time frame. Although this growth has stabilized at 58.88% in the current market session, the persistent bullish trend has traders eagerly anticipating further gain throughout the day.

The Shanghai-based healthcare integrated solutions provider is positioned to enter unprecedented growth after a string of deals signed with global industry players. Optimists suggest these developments could in fact lead to the creation of potential synergies and subsequent share value. Back in mid-February, ECMOHO’s announcement of an agreement of cooperation with US-based vitamin and supplements global retailer, Vitamin Worldhad denoted a significant shift in the company’s perspective trajectory. ECMOHO has agreed to market and sell Vitamin World’s quality products to the lucrative Chinese consumer markets on popular e-commerce portals such as T-mall and the JD Platform. Vitamin World, being an established player in the global industry, with experience spanning 45 years, offers to bring professionalism, and a high degree of innovation into the partnership. This is in line with the vision of ECMOHO to commit to a strengthened digital markets strategy.

The Digital Marketing Front

Similarly, ECMOHO Limited has been engaged in brand-building initiatives, specifically focused on the youth. By initiating informative health-related content on TikTok, as well as similar posts on other social media platforms in China, the brand is establishing itself as a reliable player within the market which holds the trust of its target demographic.

Conclusion

The MOHO stock has impressed onlookers throughout the day, well into the current market session, with growth appearing sustainable. This bullish trend is backed by genuine confidence in the affairs of the company. It further reflects a potential turn of events, bringing ECMOHO onto the spotlights of the Chinese healthcare market, as a professional and reliable player.

Traders across the world looking to invest in the stock of Qiwi PLC (QIWI) woke up to news on Monday that NASDAQ had suspended trading for the stock, amongst other Russian-based financial securities. The exchange had clarified that these halts in trading were enforced in order to meet the requirements of the regulatory framework, as a result of the recently imposed economic sanctions on Russia. These developments make the prospects of the QIWI stock appear grim, with the loss in liquidity causing a further decline in the intrinsic value for the stock.

Invasion of Ukraine & Economic Response

Since Russian forces initiated the invasion of Ukraine on Wednesday last week, Russian-based stocks had seen a mass plummet, sparked by a widespread sell-off. This market-wide downward spiral had been sparked by uncertainties surrounding the economic future, as well as the possibilities of punishing sanctions. This coincided with a surge seen in US-based defense stocks of an equal proportion, again which is clearly understandable, given the expected increase in the defense budgets of NATO countries.

Despite the inherent risks surrounding Russian stocks, the QIWI stock saw remarkable growth of up to 14.8%, a mere day after the invasion began, after investors rushed to buy back stocks that were sold amidst the bleak future. The brief surge followed hesitation by a number of prominent EU member states showing hesitance in cutting the Russian banking system off SWIFT, which brought relief to investors. This however was short lasted, as trading of the Russian-based stock was shut down earlier on Monday, which seriously restricted stock liquidity.

Uncertainty regarding QIWI, as well as other Russian-based publicly listed stocks is likely to persist, which puts the future trajectory of these stocks towards a downward spiral. Given the weight of the sanctions on the Russian Federation (which is being dubbed a financial war) institutions are increasingly distancing themselves from Russian assets. Those holding the QIWI stock are unable to sell off the security, despite a fall in intrinsic value, given trade suspension on NASDAQ.

Conclusion

QIWI stock, along with other Russian-based tradeable securities are no longer available for buy and sell in NASDAQ, following regulatory measures in line with global sanctions against the Russian Federation. As a result, the future for Russian equities continues to look bleak amidst the market-wide plummet.

Brickell Biotech Inc. (BBI) shares were rising 2.39% to trade at $0.22 in the current market at the last check. BBI’s stock closed the previous session at $0.22. The stock volume remained 7.13 million shares, which was lower than the average daily volume of 8.86 million shares within the past 50 days.

Licensing for Exclusive Global Rights

The positive stock performance comes after the announcement of the biotech company’s acquisition of global exclusive rights of NOVEL Sting inhibitors – a crucial mode of treatment inflammatory, as well as autoimmune diseases. This is in reference to a licensing agreement signed last month with Carna Biosciences Inc, a biochemical company, specializing in clinical trial procedures of treatment development.

The licensing arrangement promises to boost Brickell Biotech’s (BBI) growth trajectory, pushing it towards new domains, and capturing newfound opportunities. Specifically, working with STING inhibitors would allow for Brickell Biotech to step into the fields of immunology as well as inflammation, which are crucial sub-sectors of biopharmaceuticals. Statements from the CEO of Brickell, Robert Brown, indicate that the company’s projects are in line with its broader strategy towards expansion, whilst management remains optimistic about target achievements.

Observed Stock Volatility

Despite these positive developments and earlier growth spurts in stock price observed, there appears to be significant volatility in the pre-market session. The volatility of this nature indicates divided perspectives regarding stock direction. Concerns had been raised earlier on regarding a form 4 filing by the company, indicating a change in beneficial ownership. A disposal of 15,180 shares was reported by the chairman of the board. However, this disposal merely reflected less than 2% of the officer’s overall ownership of BBI stock.

Pharmaceutical Shift in Industry

The BBI stock climb coincides with other gains in the pharmaceuticals industry, where investments are being made towards non-covid related treatments, following milestones achieved in terms of the Coronavirus pandemic. High rates of vaccination and easing containment restrictions signal the nearing end of the pandemic and a potential downgrade to endemic status. As a result, other domains in the healthcare industry, such as immunology and inflammation are garnering attention once more, as is the case with Brickell’s licensing agreement. The likelihood of attention to this domain, as well as allocation of investment funds to these areas, holds optimism for stocks such as BBI.

Conclusion

The BBI stock has been turning heads of traders in the current market hours, with remarkable short-term growth, yet the volatility observed continues to remain a cause for concern. An earlier licensing agreement signed with Carna Biosciences spells potential for expansion, which becomes likely in a post-Covid context.

Stock of Imperial Petroleum (IMPP) has been on the forefront of today’s gainers in NASDAQ’s current market session. During the regular trading, the stock had closed at $1.48, which was a decline of 37.55% from its opening amount of $2.22. However, the stock had proven to be a gamechanger in the current market, seeing an increase of 39.18%. IMPP has clearly been caught up in a meme stock frenzy, brought about by retail investors on Reddit and Twitter.

Irregularities in the Oil Markets

The stock has been following a trend of continuous gain since Wednesday of last week, coinciding with Russia’s invasion of Ukraine, an event likely to push the world towards a significant oil crisis. The sanctions on oil-producing Russia, as well as increasing demand with the easing of Covid restrictions, continue to drive up oil prices. The announcement by the International Energy Agency (IEA) to deploy 60 million barrels of crude oil from its energy reserves has brought a collective sigh of relief across the oil market.

Imperial Petroleum, the once wholly-owned subsidiary of StealthGas Inc, upon completion of its spin-off, gained independent status from its parent company earlier in December. Ever since then, the stock was closely watched by traders and persisted in earning massive strides owing to rising oil prices. These circumstances saw the stock gaining by upwards of 280% last month alone. The current hype around the IMPP stock is suggestive of a similar price climb as was experienced last month.

Ambitions of Expansion

Imperial Petroleum (IMPP) did face backlash from investors, upon declaring intentions to expand its fleet, which it would fund through equity funding. As a result, existing stockholders would see a dilution of their shares in the company. Seasoned traders have warned against this, claiming that the company’s small size does not justify its net asset value per share. However, retail investors caught up in the social media frenzy surrounding the stock are less concerned with technical feasibilities, and more so with immediate swings with the stock. The substantial trade volume is an indicator of this hype, with most traders betting on the oil market irregularities amidst the Ukraine crisis to deliver ample gains.

Conclusion

The IMPP stock seems to be caught up in a trader’s frenzy hyped by social media. The gains it has delivered have been remarkable, and are moving along closely with increasing crude oil prices. The stock has been watched closely since its spinoff from the parent company, StealthGas, as well as its ambitions to expand its fleet.